Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 2/Phase 3

Effect of Early Administration of TXA in Adult Hip Fractures

Ascension Health · NCT05047133

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 2, Phase 3
Target enrollment
170
US sites recruiting
1
Study start
September 1, 2021
Record last updated
September 16, 2021

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Being studied: Tranexamic acid

Conditions: Postoperative Blood Loss

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 1. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation

Exclusion Criteria

  • Polytrauma patients
  • Previous operation on the ipsilateral hip
  • Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
  • Patients with \< 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)
  • History of seizure disorder
  • Patients on birth control
  • Pregnant Women
  • Prisoners
  • Active thromboembolic disease (DVT/PE, MI, Stroke)

Recruiting US locations

  • Ascension Genesys Hospital

    Grand Blanc, MI 48439

    Site contact: Sandra Watt, MS, BSN · 810-606-7713 · sandra.watt@ascension.org

Study contacts (from the official record)

  • Jacob Hinkley, DO, MS · 810-606-5669 · jacob.hinkley2@ascension.org
  • Jacob Lytle, DO · 810-606-5669 · jacob.lytle@ascension.org
All healthy volunteers studies in Michigan →